Indolin-2-one derivatives

US10377746B2 · kind B2 · utility

Assignee

• Hoffmann-La Roche Inc. · US

Inventors

• Delphine Gaufreteau · Bartenheim, FR
• Hans Hilpert · Reinach, CH
• Roland Humm · Auggen, DE
• Sabine Kolczewski · Lörrach, DE
• Thorsten Muser · Soest, DE
• Jean-Marc Plancher · Rixheim, FR
• Theodor Stoll · Basel, CH

Key dates

• Filing date: May 4, 2018
• Grant date: Aug 13, 2019
• Expiry date: May 4, 2038

Classification

• Technology area (CPC A): Human Necessities
• CPC primary: A61K2300/00
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The present invention is concerned with indolin-2-one derivatives of general formula The compounds may be used in the treatment of CNS diseases related to positive (psychosis) and negative symptoms of schizophrenia, substance abuse, alcohol and drug addiction, obsessive-compulsive disorders, cognitive impairment, bipolar disorders, mood disorders, major depression, treatment resistant depression, anxiety disorders, Alzheimer's disease, autism, Parkinson's disease, chronic pain, borderline personality disorder, neurodegenerative disease, sleep disturbances, chronic fatigue syndrome, stiffness, inflammatory disease, asthma, Huntington's disease, ADHD, amyotrophic lateral sclerosis, effects in arthritis, autoimmune disease, viral and fungal infections, cardiovascular diseases, ophthalmology and inflammatory retinal diseases and balance problems, epilepsy and neurodevelopmental disorders with co-morbid epilepsy.